Daclatinib combined with bevacizumab is effective, but need to combine with the patient’s situation to determine. Daclatinib and bevacizumab are the first-line targeted drugs for the treatment of non-small lung cancer in clinic, and the two drugs do not have any incompatible components, so they can be combined together, and the drug components can precisely act on the tumor tissues, inhibit the activity of DDR1 and EPHA6, prevent the tumor from generating blood vessels, and block the supply of nutrients to achieve the purpose of shrinking the tumor. However, during the process of using the drug, patients may experience adverse reactions such as skin rash, onychomycosis, hypertension, proteinuria, etc. It is necessary to do a good job of observation and follow the doctor’s instructions to standardize and rationalize the use of drugs, and if the side effects are serious, the treatment can be suspended.